AbbVie fights to invalidate Novartis patents

AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus (HCV) are invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novartis secures victory as MS drug patent is upheld

18 August 2020 In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Americas

Novartis accused of owing $47m in IP royalties

15 July 2021 Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.

Americas

Novartis upholds MS drug patent at Fed Circ

4 January 2022 Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.

More on this story

Big Pharma

Novartis secures victory as MS drug patent is upheld

18 August 2020 In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Americas

Novartis accused of owing $47m in IP royalties

15 July 2021 Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.

Americas

Novartis upholds MS drug patent at Fed Circ

More on this story

Big Pharma

Novartis secures victory as MS drug patent is upheld

18 August 2020 In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Americas

Novartis accused of owing $47m in IP royalties

15 July 2021 Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.

Americas

Novartis upholds MS drug patent at Fed Circ